Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

81. Perampanel (Fycompa) - for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

Perampanel (Fycompa) - for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. Published 12 August 2019 www.scottishmedicines.org.uk Statement of advice SMC2218 perampanel 0.5mg/mL oral suspension (Fycompa®) Eisai Ltd 5 July 2019 Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish (...) with the patient and/or guardian or carer. Chairman Scottish Medicines Consortium ADVICE: in the absence of a submission from the holder of the marketing authorisation perampanel (Fycompa®) is not recommended for use within NHSScotland. Indication under review: for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding

2019 Scottish Medicines Consortium

82. Perampanel (Fycompa) - for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.

Perampanel (Fycompa) - for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. Published 12 August 2019 1 Product update SMC2172 perampanel 0.5mg/mL oral suspension (Fycompa®) Eisai Ltd 5 July 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission perampanel (Fycompa®) is accepted for restricted use within NHSScotland. Indication under review: for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. SMC restriction: use as a second-line adjunctive treatment in patients with refractory partial onset epilepsy who are unable to swallow

2019 Scottish Medicines Consortium

83. Felbamate add-on therapy for drug-resistant focal epilepsy. Full Text available with Trip Pro

Felbamate add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review previously published in 2017.Epilepsy is a chronic and disabling neurological disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available antiepileptic drugs and require treatment with multiple antiepileptic drugs in combination. Felbamate is a second-generation antiepileptic drug that can be used (...) to search for additional reports of relevant studies. We also contacted the manufacturers of felbamate and experts in the field for information about any unpublished or ongoing studies.We searched for randomised placebo-controlled add-on studies of people of any age with drug-resistant focal seizures. The studies could be double-blind, single-blind or unblinded and could be of parallel-group or cross-over design.Two review authors independently selected studies for inclusion and extracted information

2019 Cochrane

84. Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review. Full Text available with Trip Pro

Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review. This is an update of a Cochrane Review first published in 2001, and last updated in 2013. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals (...) with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, particularly in the developing world, phenytoin and phenobarbitone are commonly used antiepileptic drugs, primarily because they are inexpensive. The aim of this review is to summarise data from existing trials comparing phenytoin and phenobarbitone.To review the time to treatment failure, remission and first seizure

2019 Cochrane

85. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Full Text available with Trip Pro

with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, carbamazepine and phenytoin are commonly-used broad spectrum antiepileptic drugs, suitable for most epileptic seizure types. Carbamazepine is a current first-line treatment for focal onset seizures in the USA and Europe. Phenytoin is no longer considered a first-line treatment, due to concerns over adverse events (...) Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. This is an update of a Cochrane Review first published in 2002 and last updated in 2017. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals

2019 Cochrane

86. Pregabalin add-on for drug-resistant focal epilepsy. Full Text available with Trip Pro

Pregabalin add-on for drug-resistant focal epilepsy. Epilepsy is a common neurological disease that affects approximately 1% of the UK population. Approximately one-third of these people continue to have seizures despite drug treatment. Pregabalin is one of the newer antiepileptic drugs which have been developed to improve outcomes.This is an updated version of the Cochrane Review published in Issue 3, 2014, and includes three new studies.To assess the efficacy and tolerability of pregabalin (...) , manufacturer of pregabalin, to identify published, unpublished, and ongoing trials.We included randomised controlled trials comparing pregabalin with placebo or an alternative antiepileptic drug as an add-on for people of any age with drug-resistant focal epilepsy. Double-blind and single-blind trials were eligible for inclusion. The primary outcome was 50% or greater reduction in seizure frequency; secondary outcomes were seizure freedom, treatment withdrawal for any reason, treatment withdrawal due

2019 Cochrane

87. Neonatal Seizure and Afterward, Epilepsy: A Systematic Review Full Text available with Trip Pro

. 2006;117(4):1270-80. Michelle B, Pierre G, Charlotte D. Epileptic syndromes in infancy, childhood and adolescence: John Libbey Eurotext; 2012. Pisani F, Piccolo B, Cantalupo G, Copioli C, Fusco C, Pelosi A, et al. Neonatal seizures and postneonatal epilepsy: a 7-y follow-up study. 2012;72(2):186. Connell J, Oozeer R, De Vries L, Dubowitz L, Dubowitz VJAodic. Continuous EEG monitoring of neonatal seizures: diagnostic and prognostic considerations. 1989;64(4 Spec No):452-8. Khan RL, Lahorgue Nunes M (...) -epileptic drugs during the neonatal period. 2012;88(1):33-8. Yıldız EP, Tatlı B, Ekici B, Eraslan E, Aydınlı N, Çalışkan M, et al. Evaluation of etiologic and prognostic factors in neonatal convulsions. 2012;47(3):186-92. Lai Y-H, Ho C-S, Chiu N-C, Tseng C-F, Huang Y-LJP, Neonatology. Prognostic factors of developmental outcome in neonatal seizures in term infants. 2013;54(3):166-72. Sidiq B, Herini ES, Wibowo TJPI. Prognostic factors of epilepsy in patients with neonatal seizures history. 2013;53(4):18

2019 International Clinical Neuroscience Journal

88. P263 Investigation of the first afebrile seizure in the paediatric ED: a systematic review Full Text available with Trip Pro

P263 Investigation of the first afebrile seizure in the paediatric ED: a systematic review P263 Investigation of the first afebrile seizure in the paediatric ED: a systematic review | Archives of Disease in Childhood Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? You are here P263 Investigation of the first afebrile seizure in the paediatric ED: a systematic review Article Text Abstracts P263 Investigation of the first afebrile seizure in the paediatric ED: a systematic review Free Haaris Aziz Shiwani , Eoin MacMeanmain , Evan Hurley-O’Dwyer , Grace Rothwell-Kelly , Nicholas Arrotta , Louise Sweeney , Danyal Memon , Shaheer Aziz , Mohammad Danish Yusuf , Hadeer Ameen , Eleanor Molloy Statistics

2019 Abstracts

89. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Full Text available with Trip Pro

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management (...) of paediatric convulsive status epilepticus.This open-label, randomised clinical trial was undertaken at 30 UK emergency departments at secondary and tertiary care centres. Participants aged 6 months to under 18 years, with convulsive status epilepticus requiring second-line treatment, were randomly assigned (1:1) using a computer-generated randomisation schedule to receive levetiracetam (40 mg/kg over 5 min) or phenytoin (20 mg/kg over at least 20 min), stratified by centre. The primary outcome was time

2019 Lancet

90. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. (Abstract)

Zealand Clinical Trials Registry, number ACTRN12615000129583.Between March 19, 2015, and Nov 29, 2017, 639 children presented to participating emergency departments with convulsive status epilepticus; 127 were missed, and 278 did not meet eligibility criteria. The parents of one child declined to give consent, leaving 233 children (114 assigned to phenytoin and 119 assigned to levetiracetam) in the intention-to-treat population. Clinical cessation of seizure activity 5 min after completion of infusion (...) Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Phenytoin is the current standard of care for second-line treatment of paediatric convulsive status epilepticus after failure of first-line benzodiazepines, but is only effective in 60% of cases and is associated with considerable adverse effects. A newer anticonvulsant, levetiracetam, can be given more quickly, is potentially

2019 Lancet Controlled trial quality: predicted high

91. Rufinamide (Inovelon) - as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome

Rufinamide (Inovelon) - as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome Published 08 April 2019 1 www.scottishmedicines.org.uk Product update SMC2146 rufinamide 40mg/mL oral suspension and 100mg, 200mg, 400mg tablets (Inovelon®) Eisai Limited 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission rufinamide (Inovelon®) is accepted for restricted use within NHSScotland. Indication under review: as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to =4 years. SMC restriction: restricted to use in patients who have failed treatment with or are intolerant of other antiepileptic drugs. Rufinamide (Inovelon®) has previously been accepted for restricted use in adults and children

2019 Scottish Medicines Consortium

92. Radiosurgery Techniques in the Treatment of Epilepsy Related to Hypothalamic Hamartomas (Systematic Review) Full Text available with Trip Pro

:81–7. . 21. Wieser HG, Blume WT, Fish D, et al. ILAE commission report. Proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia. 2001;42:282–6. . 22. Harvey AS, Freeman JL, Berkovic SF, Rosenfeld JV. Transcallosal resection of hypothalamic hamartomas in patients with intractable epilepsy. Epileptic Disord. 2003;5:257–65. 23. Mathieu D, Deacon C, Pinard CA, et al. Gamma knife surgery for hypothalamic hamartomas causing refractory (...) for the therapy of epilepsy related to hypothalamic hamartomas (HH). As shown in previous reports, each RS method can reduce the frequency of seizures, as well as behavioral and cognitive alterations related to HH. This review summarizes the safety and efficacy of the most frequently used RS techniques for HH patients, with a particular focus on the Gamma Knife RS, interstitial brachytherapy, and linear accelerator (LINAC) RS. Literature compilation was achieved through use of a wide spectrum of information

2019 SN Comprehensive Clinical Medicine

93. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Full Text available with Trip Pro

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the Cochrane Review previously published in 2017.Absence seizures (AS) are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences are characterised by sudden loss of awareness (...) and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with AS.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other.For the latest update we searched

2019 Cochrane

94. Simple febrile seizures in a child. First-choice treatments

% of febrile seizures in children are classified as "complex" and require specific treatment by an emergency medical service as well as hospitalisation in order to investigate the cause. A complex seizure presents at least one of the following features: duration of more than 15 minutes; recurrence within 24 hours; partial seizure , i.e. with convulsions affecting only part of the body, without loss of consciousness; neurological disorder following the seizure. Situations in which there is a risk (...) -choice treatments FEATURED REVIEW Febrile seizures occur in around 3% of children. What are the essential points for healthcare professionals to keep in mind? And what are the warning signs to look out for? Full review (4 pages) available for download by subscribers. A simple febrile seizure is defined as an episode of generalised seizures lasting less than 15 minutes and occurring only once in 24 hours in a child during a febrile episode, without intracranial infection, metabolic disorders

2019 Prescrire

95. Eslicarbazepine acetate (Zebinix) - as adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures

in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission eslicarbazepine acetate (Zebinix ® ) is accepted for restricted use within NHSScotland. Indication under review: as adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation. SMC restriction: patients with highly refractory epilepsy who have been heavily pre-treated and remain uncontrolled with existing anti-epileptic drugs. SMC (...) Eslicarbazepine acetate (Zebinix) - as adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures Published 11 February 2019 Product Update: eslicarbazepine acetate 200mg and 800mg tablets and oral suspension 50mg/mL (Zebinix ® ) SMC2087 Eisai Ltd 10 August 2018 (Issued 11 January 2019) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use

2019 Scottish Medicines Consortium

96. Epilepsy in adults. (Abstract)

expression and cause. These advances have resulted in the new classification of epileptic seizures and epilepsies. A detailed clinical history and a reliable eyewitness account of a seizure are the cornerstones of the diagnosis. Ancillary investigations can help to determine cause and prognosis. Advances in brain imaging are helping to identify the structural and functional causes and consequences of the epilepsies. Comorbidities are increasingly recognised as important aetiological and prognostic (...) markers. Antiseizure medication might suppress seizures in up to two-thirds of all individuals but do not alter long-term prognosis. Epilepsy surgery is the most effective way to achieve long-term seizure freedom in selected individuals with drug-resistant focal epilepsy, but it is probably not used enough. With improved understanding of the gradual development of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modifying, or even curative, pharmacological

2019 Lancet

97. Febrile seizure

?tool=bestpractice.com The 2006 report by the International League Against Epilepsy Task Force on Classification and Terminology of Epilepsy and Epileptic Syndromes proposed a change in terminology and the omission of the words 'convulsion' and 'convulsive'. They suggested that the term 'febrile convulsions' be replaced by 'febrile seizures'. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE (...) Febrile seizure Febrile seizure - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Febrile seizure Last reviewed: February 2019 Last updated: January 2019 Summary Febrile seizures are usually self-limiting; an increased risk of developing epilepsy is low except in a small number of cases. Most febrile seizures resolve spontaneously and quickly, and do not require acute or long-term anticonvulsant treatment. Definition

2019 BMJ Best Practice

98. Brivaracetam (epilepsy) - Benefit assessment in accordance with §35a Social Code Book V

for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: No advisor on medical and scientific questions was available for the present dossier assessment. IQWiG employees involved in the dossier assessment: ? Anke Penno ? Gertrud Egger ? Charlotte Guddat ? Tatjana Hermanns ? Stefan Kobza ? Min Ripoll ? Cornelia Rüdig ? Volker Vervölgyi Keywords: brivaracetam, epilepsies – partial, seizures, child, adolescent, benefit assessment Extract of dossier assessment A18-48 Version 1.0 (...) to as the “company”). The dossier was sent to IQWiG on 30 July 2018. Research question The aim of this report is to assess the added benefit of brivaracetam as adjunctive therapy for partial seizures with or without secondary generalization in children and adolescents aged = 4 to < 16 years with epilepsy in comparison with the appropriate comparator therapy (ACT). The ACT specified by the G-BA served as the basis for the research question presented in Table 2 for this benefit assessment. Table 2 2 : Research

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

99. Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines

threshold, for example, antidepressants and antipsychotics. Serotonin syndrome has also been reported when tapentadol is used in combination with serotoninergic antidepressants. Published 9 January 2019 Last updated 9 January 2019 — From: Therapeutic area: , , , Contents Advice for healthcare professionals: as for all opioid medicines, tapentadol can induce seizures tapentadol should be prescribed with care in patients with a history of seizure disorders or epilepsy tapentadol may increase seizure risk (...) include selective serotonin-reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and antipsychotics. Tapentadol should be used with care in patients with a history of seizure disorders or epilepsy because of the increased risk of seizures. Strengthened warnings on seizure risk have been added to the Summary of Product Characteristics and Patient Information Leaflets. Reports of serotonin syndrome We are also aware of reports of serotonin

2019 MHRA Drug Safety Update

100. A Prediction Model to Determine Childhood Epilepsy After 1 or More Paroxysmal Events Full Text available with Trip Pro

A Prediction Model to Determine Childhood Epilepsy After 1 or More Paroxysmal Events The clinical profile of children who had possible seizures is heterogeneous, and accuracy of diagnostic testing is limited. We aimed to develop and validate a prediction model that determines the risk of childhood epilepsy by combining available information at first consultation.We retrospectively collected data of 451 children who visited our outpatient department for diagnostic workup related to 1 or more (...) paroxysmal event(s). At least 1 year of follow-up was available for all children who were diagnosed with epilepsy or in whom diagnosis remained inconclusive. Clinical characteristics (sex, age of first seizure, event description, medical history) and EEG report were used as predictor variables for building a multivariate logistic regression model. Performance was validated in an external cohort (n = 187).Model discrimination was excellent, with an area under the receiver operating characteristic curve

2019 EvidenceUpdates